USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: NEOCLONE BIOTECHNOLOGY INTERNATIONAL
Address: 1202 Ann St
MADISON, WI 53713-2410
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,640,419.00 6
SBIR Phase II $206,777.00 1
STTR Phase I $190,591.00 1

Award List:

BIOMARK SCRN W REVOLUTIONARY NEOAB ANTIBODIES

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rachel Kravitz
Award Amount: $100,000.00

Novel Platform Technology for Developing Therapeutic Human mAbs

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rachel H. Kravitz
Award Amount: $140,000.00
Abstract:
DESCRIPTION (provided by applicant): Despite significant advances in treatment and early detection, cancer remains a significant disease threat to society. Therapeutic monoclonal antibodies are effective new treatments that have recently been developed as targeted therapies against many types of… More

A novel platform for mining the repertoire of antigen-specific B cells

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ward C. Tucker
Award Amount: $99,635.00
Abstract:
DESCRIPTION (provided by applicant): Cancer remains a significant threat to the health and economy of today's society. Advances in cancer research are key to cancer biomarker discovery, development of rapid and reliable methods of cancer-specific di agnosis, and development of new treatments.… More

BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tucker Ward
Award Amount: $507,208.00

BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tucker Ward
Award Amount: $507,208.00

BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $206,777.00
Abstract:
Not Available

Improving Ovarian Cancer Treatment by Targeting a Novel Epitope of MUC16

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF WISCONSIN MADISON
Principal Investigator: Rachel H. Kravitz
Award Amount: $190,591.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The CA125 antigen is a well known marker for monitoring the recurrence and progression of epithelial ovarian cancer. It is now clear that this antigen is a repeating peptide epitope that is present within the protein ba ckbone of the recently identified mucin… More

Reactivation of human cells for novel fully human Ab platform

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rachel H. Kravitz – 608-260-8190
Award Amount: $286,368.00
Abstract:
DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) have been developed into a highly effective class of therapeutic molecules, with global growth of 37% between 2001 and 2002. Since their discovery in 1975, mAbs have been described as magic bullets with the potential to seek out… More